On the contrary, anti-IL-1β-directed therapies hold promise for chemoprevention, as shown by the CANTOS trial, (where tri-monthly administration of the IL-1β-neutralizing antibody canakinumab over 3.7 years of observation decreased overall and lung cancer mortality by 51% and 77%, respectively) based on their excellent safety profile [2]. The gene discussed is IL1B; the disease is lung carcinoma.